Treatment Selection

What is the Role of the Treatment Selection Working Group?

Our Treatment Selection Working Group is responsible for deciding the first round of treatments selected for testing in the trial. They are deciding how and where potential treatments are identified and the best way to score them so that those with the most potential to have an effect are selected.

Meet the Chairs

Professor Tony Schapira

Professor Tony Schapira is head of the Department of Clinical and Movement Neurosciences at UCL Queen Square Institute of Neurology, and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery and the Royal Free London Hospital.

Professor Schapira’s research interests include the molecular, genetic and clinical aspects of Parkinson disease and the development of drugs for slowing its progress.

Professor Schapira co-leads our Treatment Selection Working Group with Professor Oliver Bandmann.

Professor Oliver Bandmann

Prof. Bandmann is Professor of Movement Disorders Neurology and Honorary Consultant Neurologist at the University of Sheffield.

Prof. Bandmann’s research focuses on movement disorders, with a particular interest in working towards disease-modifying therapy for Parkinson’s Disease to slow down progression.

Professor Bandmann co-leads our Treatment Selection Working Group which is tasked with developing a robust and transparent process by which to score and shortlist treatments with the greatest neuroprotective potential for entry into the EJS ACT-PD trial.

Members of this working group

Edwin Jabbari, Early Career Researcher University College London
Simon Stott Cure Parkinson’s Trust, London
George Tofaris University of Oxford
Esther Sammler University of Dundee
Heather Mortiboys University of Sheffield
Li Wei University College London
Alan Wong Royal Free London, NHS Foundation Trust
Susan Duty Kings College London
David Dexter Parkinson’s UK, London
Paula Scurfield PPI member, Kent
Kevin McFarthing PPI member, London